AeroLeads people directory · profile
Stevan Djakovic Email & Phone Number
Senior Director, Clinical Research
at
ArriVent Biopharma
1 work email found
@gene.com
2 phones found area 858
LinkedIn matched
✓ Verified July 2026
4 data sources
Profile completeness 100%
Current company
Role
Senior Director, Clinical Research
Location
San Francisco, California, United States
Company size
Who is Stevan Djakovic? Overview
A concise factual answer block for searchers comparing this professional profile.
Quick answer
Stevan Djakovic is listed as Senior Director, Clinical Research at ArriVent Biopharma, a with 67 employees, based in San Francisco, California, United States. AeroLeads shows a work email signal at gene.com, phone signal with area code 858, and a matched LinkedIn profile for Stevan Djakovic.
Stevan Djakovic previously worked as Senior Principal Clinical Scientist at Genentech and Principal Clinical Scientist at Genentech. Stevan Djakovic holds Phd, Biology: Neurobiology from Uc San Diego.
Company email context
Email format at ArriVent Biopharma
This section adds company-level context without repeating Stevan Djakovic's masked contact details.
{last}.{first}@gene.com
86% confidence
AeroLeads found 1 current-domain work email signal for Stevan Djakovic. Compare company email patterns before reaching out.
Profile bio
About Stevan Djakovic
Clinical Scientist with 12+ years experience in drug discovery and development including:•9+ years clinical science experience in early and late stage solid tumor, hematology-oncology, and neurodegeneration clinical trials at both small, fast based biotechnology and large pharmaceutical companies.•Experience with FDA and EMA filing (NDA, MAA, labeling), study start up and study close down•Authoring of clinical documents (eg Protocol, IB, IND, CSR, etc).•Medical data review for individual patients or large datasets (800+ patients) in aggregate using data listing and visualization review•Experience with small molecule, therapeutic antibody, and gene therapy discovery and development•Extensive record of publishing in peer-reviewed journals and presentation at international conferences.•Demonstrated ability to establish and coordinate large multi-disciplinary CRO, academic and industry collaborations.
Listed skills include Cell Culture, Molecular Biology, Cell, Biochemistry, and 42 others.
Current workplace
Stevan Djakovic's current company
Company context helps verify the profile and gives searchers a useful next step.
Arrivent Biopharma
12 roles · 15 years
Stevan Djakovic work experience
A career timeline built from the work history available for this profile.
Senior Principal Clinical Scientist
Current
Sep 2024 - Present
Principal Clinical Scientist
Early clinical development (phase 1 and 2) of novel anti-cancer immunotherapies, including large molecules and gene therapies
Jun 2022 - Sep 2024
Senior Clinical Scientist
Early clinical development (phase 1 and 2) of novel anti-cancer immunotherapies, including large molecules and gene therapies
Sep 2020 - Jun 2022
Lead Clinical Scientist
Clinical Scientist supporting early stage (Phase 1 and 2) clinical development in oncology.
May 2019 - Sep 2020
Clinical Scientist Associate
Clinical Scientist supporting late stage (Phase 2 and 3) clinical development:- 2018-2019: Phase 3 neurodegeneration studies (e.g., Alzheimer's Disease)- 2017-2018: Phase 2 and 3 lymphoid hematological malignancy (e.g., CLL and NHL) studies, including FDA and EMA filing experience.
May 2017 - May 2019
Clinical Scientist
- Early stage clinical development of CB-5083 for solid tumor and heme oncology indications- Worked closely with CMO and medical monitor to design and implement the CDP- Collaborated with DM and clin ops for EDC design and revisions and data review/cleaning - Lead author and major contributor to clinical protocols, IND, IB, CRF, ICF and other regulatory submissions - Involved in site selection, vendor selection and KOL/site interface; including organizing and presenting at SIVs - Responsible for managing the development and implementation of clinical pharmacodynamics and patient enrichment biomarkers and strategies (and eventual CDx development).
Aug 2015 - May 2017
Associate Scientist ->Scientist
Discovery and development of novel small molecule therapeutics targeting protein homeostasis pathways for oncology indications.- Oversee high-content cell-based compound screening, drug mechanism of action and combination studies.- Collaborate with the translational biology group for clinical biomarker discovery and development and patient enrichment studies.- Manage external academic collaborations.- Involved in new target discovery/validation, assay development, high throughput screening and regulatory filings.- Involved in lead optimization and preclinical development of CB-5083, which was tested in phase 1 clinical trials for oncology indications.Selected Publication:Anderson DJ, LeMoigne R, Djakovic S, Kumar B, Rice J, Wong S, Wang J, Yao B, Valle E, KissvonSoly S, Madriaga A, Soriano F, Menon M, Wu ZY, Kampmann M, Chen Y, Weissman J, Aftab B, Yakes FM, Shawver L, Zho H, Wustrow D, Rolfe M. Targeting the AAA ATPase, p97, as a novel approach to treat cancer through disruption of protein homeostasis. Cancer Cell. 2015.
Jan 2013 - Oct 2015
Senior Research Associate
SRA (contract) reporting to Avi Ashkenazi in the Department of Molecular Oncology involved in discovery of cancer therapeutics. - Collaborated with antibody engineering to generate novel dual specificity antibodies targeting two RTK oncogenes.- Developed a cell based screen to identify hits.- Successfully characterized antibodies and assessed in vitro efficacy.- Selected lead antibodies that were tested for efficacy in xenograft models.Selected Publication:Yin Y, Djakovic SN, Marsters S, Tien J, Peng J, Tremayne J, Lee G, Neve R, Wu Y, Merchant M, Ashkenazi A, Carter PJ. Redesigning a monospecific anti-FGFR3 antibody to add selectivity for FGFR2 and expand anti-tumor activity. Molecular Cancer Therapeutics. 2015.
2012 - 2013
~1 yr
Postdoctoral Fellow
• Project: To investigate the role of autophagy and mitophagy in neurodegenerative disease• Collaborated with multiple academic and biotech labs in translational research projects• Became skilled in mouse genetics, molecular biology and biochemistry • Trained and supervised 2 undergraduates and 1 graduate student • Postdoctoral Fellowship - NIH Neuroplasticity of Aging Training GrantSelected Publication:Dubinsky A, Dastidar S, Hsu C, Zahra R, Djakovic SN, Duarte S, Esau C, Spencer B, Ashe T, Fischer K, MacKenna D, Sopher B, Masliah E, Gaasterland T, Chau N, Almeida L, Morrison B, La Spada A. Let-7 coordinately suppresses components of the amino acid sensing pathway to repress mTORC1 and induce autophagy. Cell Metabolism, 2014.
Jun 2010 - Dec 2012
Doctoral Researcher
- PhD in Biology, with a focus on neuroscience from the laboratory of Dr. Gentry Patrick. - Developed novel live imaging based reporter assays to investigate the role of the ubiquitin proteasome system in synaptic function and neurodegenerative disease. - Author on 5 publications.- Helped setup the lab (ordering, hiring, protocol establishment, administration).- Managed and supervised undergraduate and high school interns/employees.- Funded by the Neuroplasticity of Aging training grant.- Established viral based gene delivery system for the lab. Also assisted/collaborated with other labs on viral projects leading to 1 authorship and 4 acknowledgements.Selected Publication:Djakovic S, Marquez-Lona E, Jakawich S, Wright R, Chu C, Sutton M, Patrick G. Phosphorylation of Rpt6 Regulates Synaptic Strength in Hippocampal Neurons. Journal of Neuroscience. 2012 April 11.
Sep 2004 - May 2010
Research Associate
Worked as a research associate in the laboratory of Laurie G. Smith. Investigated the role of the actin cytoskeleton in plant cell morphogenesis using molecular and genetic techniques and Arabidopsis Thaliana as a model system.Selected Publication:Djakovic S, Dyachok J, Burke M, Frank MJ, Smith LG. BRICK1/HSPC300 functions with SCAR and the ARP2/3 complex to regulate epidermal cell shape in Arabidopsis.Development. 2006 Mar;133(6):1091-100
Sep 2001 - Sep 2004
2 education records
Stevan Djakovic education
Phd, Biology: Neurobiology
Uc San Diego
Bs, Biology: Biochemistry And Cell Biology
Uc San Diego
FAQ
Frequently asked questions about Stevan Djakovic
Quick answers generated from the profile data available on this page.
What company does Stevan Djakovic work for?
Stevan Djakovic works for ArriVent Biopharma.
What is Stevan Djakovic's role at ArriVent Biopharma?
Stevan Djakovic is listed as Senior Director, Clinical Research at ArriVent Biopharma.
What is Stevan Djakovic's email address?
AeroLeads has found 1 work email signal at @gene.com for Stevan Djakovic at ArriVent Biopharma.
What is Stevan Djakovic's phone number?
AeroLeads has found 2 phone signal(s) with area code 858 for Stevan Djakovic at ArriVent Biopharma.
Where is Stevan Djakovic based?
Stevan Djakovic is based in San Francisco, California, United States while working with ArriVent Biopharma.
What companies has Stevan Djakovic worked for?
Stevan Djakovic has worked for Arrivent Biopharma, Genentech, Cleave Biosciences, Inc., and Uc San Diego.
How can I contact Stevan Djakovic?
You can use AeroLeads to view verified contact signals for Stevan Djakovic at ArriVent Biopharma, including work email, phone, and LinkedIn data when available.
What schools did Stevan Djakovic attend?
Stevan Djakovic holds Phd, Biology: Neurobiology from Uc San Diego.
What skills is Stevan Djakovic known for?
Stevan Djakovic is listed with skills including Cell Culture, Molecular Biology, Cell, Biochemistry, Cell Biology, Biotechnology, Assay Development, and Confocal Microscopy.
Find 750M verified contacts
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial